IFNG and tuberous sclerosis: Recently, we demonstrated that exogenous IFN-γ is an effective single agent in the treatment of TSC-related lesions in mouse models [10] and the combination of CCI-779 plus IFN-γ was more effective than single agents in a nude mouse model [11].